<DOC>
	<DOCNO>NCT02724085</DOCNO>
	<brief_summary>This single-center , randomize , placebo-controlled , double-blind , single-ascending-dose , inpatient study ass safety , tolerability , pharmacokinetics TP‑271 healthy subject . Subjects age 18 50 year fulfill inclusion/exclusion criterion enrol study .</brief_summary>
	<brief_title>A Phase 1 Study Assess Safety , Tolerability PK IV TP-271</brief_title>
	<detailed_description>Up seven cohort eight subject ( total 56 subject ) enrol . The eight subject within cohort randomize 6:2 receive single intravenous dose TP-271 placebo . The planned dos : Cohort A : 0.15 mg/kg Cohort B : 0.45 mg/kg Cohort C : 1.0 mg/kg Cohort D : 2.0 mg/kg Cohort E : 3.0 mg/kg Cohort F : 4.0 mg/kg Cohort G : 5.0 mg/kg Doses IMP administer intravenously morning Day 1 follow overnight fast ( minimum 8 hour ) . During Screening Period ( within 28 day prior subject receive TP-271 placebo ) subject assess eligibility . Each subject must sign date ICF prior undergo study-related procedure . All cohort follow study design ( Figure 1 ) . On Day -1 , subject admit study unit eligibility confirm . Subjects require stay overnight study unit Day -1 . On Day 1 , eligible subject enrol randomized receive either TP-271 placebo . Subjects require stay study unit Day 1 Day 5 ass safety obtain required PK sample . On Day 5 , subject discharge study unit . A final safety assessment perform Day 7 Day 10 follow subject 's dose IMP .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<criteria>1 . Be within age range 18 50 year , inclusive , time Screening . 2 . Voluntarily sign IRB/Research Ethics Committee ( IRB/REC ) approve ICF participate study relevant aspect study explain discuss subject undergo study related procedure . 3 . Have body mass index ( BMI ) ≥18.0 ≤33.0 kg/m2 . 4 . Be clear history , negative screen , HIV 1 2 hepatitis B C. 5 . Have ability communicate investigative site staff manner sufficient carry protocol procedure describe . 6 . Females must nonchild bear potential , either 1year postmenopausal surgically sterile ( bilateral oophorectomy , bilateral tubal ligation , complete hysterectomy ) . 7 . Male subject must willing able use barrier method birth control practice abstinence ( even vasectomy ) dose 90 day dose IMP . 1 . History and/or presence clinically significant disease disorder cardiovascular , pulmonary , renal , hepatic , neurological , gastrointestinal , psychiatric/mental disease/disorders , , opinion PI , may either put subject risk participation study , influence result study , influence subject 's ability participate study . 2 . Clinical laboratory value fall outside eligibility range specify table Appendix C exclusionary . For laboratory value include Appendix C , value outside reference range exclusionary following exception : Low Chemistry Values High Chemistry Values Out Range UA Out Range Hematology Bicarbonate ( &gt; 18 mEq/L Chloride GGT HDL Cholesterol LDH LDL Cholesterol Phosphorus Triglycerides Chloride HDL Cholesterol LDL Cholesterol Phosphorus Triglycerides High low specific gravity Cloudy Mucus Crystals Ketones ( blood glucose normal ) Hyaline cast High low pH High hematocrit Basophils Monocytes MCV MCHC MCH RBC 3 . Blood pressure pulse outside follow range exclusionary : Systolic blood pressure 85 145 mm Hg Diastolic blood pressure 50 95 mm Hg Pulse rate 45 95 beat per minute ( bpm ) 4 . Known allergy tetracycline antibiotic excipients TP271 . 5 . Clinically significant abnormal 12lead ECG , include follow : Rhythm sinus , QTc interval use Fridericia 's formula ( QTcF ) &gt; 450 msec ; Evidence second thirddegree atrioventricular ( AV ) block ; Pathological Qwaves ( define Qwave &gt; 40 msec depth &gt; 0.4 0.5 mV ) ; Evidence ventricular preexcitation ; Electrocardiographic evidence complete leave bundle branch block , right bundle branch block ( RBBB ) , incomplete LBBB ; Intraventricular conduction delay QRS duration &gt; 120 msec ; ST segment abnormality unless judge Investigator nonpathologic . 6 . History seizure . 7 . A history within 3 year Screening drug abuse ( include benzodiazepine , opioids , amphetamine , cocaine ) positive drug result Screening drug abuse . Also exclude subject test positive cannabinoids ( THCs ) . 8 . Use tobacco , nicotine , nicotinereplacement product within 3 month prior dose study drug last study visit . 9 . Typical weekly alcohol consumption 7 alcoholic drink . One drink define 1 glass beer ( approximately 10 12 oz ) 1 ( 12 oz ) beer , 1 glass wine ( approximately 4 5 oz ) , 1 glass distil spirit ( hard liquor ) contain 1 oz liquor ( 1 oz liquid approximately 30 mL ) . 10 . Alcohol consumption within 48 hour prior dose . 11 . Participation clinical trial within 10 halflives prior study treatment past 3 month halflife unknown dose plan participation another trial addition one trial . 12 . History difficulty donate blood poor venous access . 13 . Subject donate blood ( 1 unit 350 mL ) within 1 month prior receive test material plan donate prior receive test material trial . 14 . Use prescription nonprescription medication , include vitamin herbal medication , within 7 day , 5 halflives ( know ) , whichever longer , prior dose . The use acetaminophen , naproxen , ibuprofen permit except within 24 hour prior dose . ( Note : Subjects must refrain take herbal dietary supplement prescription drug therapy duration study . ) 15 . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>